Jankovic Joseph
Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA.
Neurology. 2002 Feb 26;58(4 Suppl 1):S19-32. doi: 10.1212/wnl.58.suppl_1.s19.
Despite clinical experience with levodopa for more than three decades, the role of this agent in the treatment of Parkinson's disease (PD) has not been well defined. Clearly the most effective antiparkinsonian drug, levodopa, is associated with emergence of motor complications, particularly fluctuations and dyskinesias, as well as other side effects. In addition to these limitations, there is an ongoing debate about the potential neurotoxic effects of levodopa, suggested by some in vitro studies. However, there is no support for levodopa-induced neurotoxicity from in vivo studies. This review discusses possible mechanisms of levodopa-related complications and therapeutic strategies for their prevention and management.
尽管左旋多巴已有三十多年的临床应用经验，但其在帕金森病（PD）治疗中的作用尚未得到明确界定。左旋多巴显然是最有效的抗帕金森病药物，但它会引发运动并发症，尤其是症状波动和异动症，还会产生其他副作用。除了这些局限性，一些体外研究表明左旋多巴可能存在神经毒性作用，这一问题仍在持续争论中。然而，体内研究并未支持左旋多巴诱发神经毒性的观点。本综述讨论了左旋多巴相关并发症的可能机制及其预防和管理的治疗策略。
